Understanding Retatrutide: Mechanism, Trial Results and Safety<\/title>\n\n <meta\n name=\"description\"\n content=\"Learn how retatrutide targets GLP-1, GIP and glucagon receptors, what its Phase 2 obesity trial found, and why it remains an investigational compound.\"\n >\n\n <meta name=\"robots\" content=\"index, follow, max-image-preview:large\">\n <meta name=\"author\" content=\"ALLUVI Peptide Shop\">\n\n <meta\n property=\"og:title\"\n content=\"Understanding Retatrutide: Mechanism, Trial Results and Safety\"\n >\n <meta\n property=\"og:description\"\n content=\"An evidence-based overview of retatrutide's triple-agonist mechanism, published obesity research, safety findings and investigational status.\"\n >\n <meta property=\"og:type\" content=\"article\">\n <meta\n property=\"og:image\"\n content=\"https:\/\/alluvipeptideshop.co.uk\/wp-content\/uploads\/2026\/02\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n >\n <meta property=\"og:site_name\" content=\"ALLUVI Peptide Shop\">\n\n <meta name=\"twitter:card\" content=\"summary_large_image\">\n <meta\n name=\"twitter:title\"\n content=\"Understanding Retatrutide: Mechanism, Trial Results and Safety\"\n >\n <meta\n name=\"twitter:description\"\n content=\"Explore retatrutide's triple-agonist mechanism, Phase 2 findings and important safety limitations.\"\n >\n <meta\n name=\"twitter:image\"\n content=\"https:\/\/alluvipeptideshop.co.uk\/wp-content\/uploads\/2026\/02\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n >\n\n <style>\n :root {\n --orange: #ff8000;\n --orange-dark: #cc6600;\n --black: #111111;\n --text: #333333;\n --muted: #666666;\n --light: #f8f9fa;\n --border: #dddddd;\n --warning-bg: #fff3cd;\n --warning-border: #ffc107;\n --danger-border: #dc3545;\n }\n\n * {\n box-sizing: border-box;\n }\n\n html {\n scroll-behavior: smooth;\n }\n\n body {\n margin: 0;\n background: #ffffff;\n color: var(--text);\n font-family: Arial, Helvetica, sans-serif;\n font-size: 17px;\n line-height: 1.7;\n }\n\n .article-container {\n width: min(100% - 32px, 920px);\n margin: 0 auto;\n padding: 40px 0;\n }\n\n h1,\n h2,\n h3 {\n color: var(--black);\n line-height: 1.3;\n }\n\n h1 {\n margin: 0 0 20px;\n font-size: clamp(2rem, 5vw, 3rem);\n }\n\n h2 {\n margin-top: 42px;\n padding-bottom: 8px;\n border-bottom: 3px solid var(--orange);\n font-size: clamp(1.5rem, 4vw, 2rem);\n }\n\n h3 {\n margin-top: 28px;\n font-size: 1.3rem;\n }\n\n p,\n li {\n max-width: 78ch;\n }\n\n a {\n color: var(--orange-dark);\n font-weight: 600;\n }\n\n a:hover,\n a:focus {\n color: var(--orange);\n }\n\n .intro {\n color: #444444;\n font-size: 1.1rem;\n }\n\n .article-image {\n display: block;\n width: 100%;\n max-width: 800px;\n height: auto;\n margin: 28px auto 10px;\n border: 1px solid var(--border);\n border-radius: 8px;\n }\n\n .image-caption {\n margin: 0 auto 28px;\n color: var(--muted);\n font-size: 0.9rem;\n text-align: center;\n }\n\n .key-points,\n .research-notice,\n .safety-notice {\n margin: 28px 0;\n padding: 20px;\n border-radius: 6px;\n }\n\n .key-points {\n background: var(--light);\n border-left: 5px solid var(--orange);\n }\n\n .research-notice {\n background: var(--warning-bg);\n border-left: 5px solid var(--warning-border);\n }\n\n .safety-notice {\n background: var(--light);\n border-left: 5px solid var(--danger-border);\n }\n\n .key-points h2,\n .research-notice h2,\n .safety-notice h2 {\n margin-top: 0;\n padding: 0;\n border: 0;\n font-size: 1.35rem;\n }\n\n .responsive-table {\n width: 100%;\n margin: 24px 0;\n overflow-x: auto;\n }\n\n table {\n width: 100%;\n min-width: 680px;\n border-collapse: collapse;\n }\n\n caption {\n padding: 10px 0;\n font-weight: 700;\n text-align: left;\n }\n\n th,\n td {\n padding: 12px;\n border: 1px solid var(--border);\n text-align: left;\n vertical-align: top;\n }\n\n thead {\n background: var(--black);\n color: #ffffff;\n }\n\n .faq-item {\n margin: 18px 0;\n padding: 18px 20px;\n background: var(--light);\n border: 1px solid var(--border);\n border-radius: 6px;\n }\n\n .faq-item h3 {\n margin: 0 0 8px;\n }\n\n .faq-item p {\n margin: 0;\n }\n\n .sources li {\n margin-bottom: 14px;\n }\n\n .research-button-container {\n margin: 30px 0;\n text-align: center;\n }\n\n .research-button {\n display: inline-block;\n padding: 13px 24px;\n background: var(--orange);\n color: #ffffff;\n border-radius: 5px;\n font-weight: 700;\n text-decoration: none;\n }\n\n .research-button:hover,\n .research-button:focus {\n background: var(--orange-dark);\n color: #ffffff;\n }\n\n .article-footer {\n margin-top: 42px;\n padding-top: 22px;\n border-top: 2px solid var(--border);\n color: #555555;\n font-size: 0.92rem;\n }\n\n @media (max-width: 600px) {\n body {\n font-size: 16px;\n }\n\n .article-container {\n width: min(100% - 24px, 920px);\n padding: 24px 0;\n }\n }\n <\/style>\n\n <script type=\"application\/ld+json\">{\n \"@context\": \"https:\\\/\\\/schema.org\",\n \"@type\": \"Article\",\n \"headline\": \"Understanding Retatrutide: Mechanism, Trial Results and Safety\",\n \"description\": \"An evidence-based overview of retatrutide's triple-agonist mechanism, published obesity research, safety findings and investigational status.\",\n \"image\": [\n \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n ],\n \"author\": {\n \"@type\": \"Organization\",\n \"name\": \"ALLUVI Peptide Shop\",\n \"url\": \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/\"\n },\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"ALLUVI Peptide Shop\",\n \"url\": \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/\"\n },\n \"mainEntityOfPage\": {\n \"@type\": \"WebPage\",\n \"@id\": \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/\"\n },\n \"about\": [\n {\n \"@type\": \"Thing\",\n \"name\": \"Retatrutide\"\n },\n {\n \"@type\": \"Thing\",\n \"name\": \"Obesity research\"\n },\n {\n \"@type\": \"Thing\",\n \"name\": \"Triple receptor agonist\"\n }\n ]\n}<\/script>\n<\/head>\n\n<body>\n <main>\n <article class=\"article-container\">\n <header>\n <h1>Understanding Retatrutide: Mechanism, Trial Results and Safety<\/h1>\n\n <p class=\"intro\">\n Retatrutide is an investigational peptide being studied for obesity\n and related metabolic conditions. Rather than acting only at the\n GLP-1 receptor, retatrutide is designed to activate three receptor\n systems: GLP-1, GIP and glucagon.\n <\/p>\n\n <p>\n This triple-agonist mechanism has produced notable findings in\n clinical research. However, retatrutide should not be described as an\n approved weight-loss treatment, a guaranteed fat-burning product or a\n substitute for an authorised medicine.\n <\/p>\n <\/header>\n\n <figure>\n <img decoding=\"async\"\n class=\"article-image\"\n src=\"https:\/\/alluvipeptideshop.co.uk\/wp-content\/uploads\/2026\/02\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n alt=\"Chart illustrating body-weight changes reported during retatrutide research\"\n width=\"800\"\n height=\"800\"\n loading=\"eager\"\n fetchpriority=\"high\"\n >\n <figcaption class=\"image-caption\">\n Illustration of body-weight outcomes associated with published\n retatrutide research. Study averages do not predict individual results.\n <\/figcaption>\n <\/figure>\n\n <aside class=\"key-points\" aria-labelledby=\"key-points-heading\">\n <h2 id=\"key-points-heading\">Key Points<\/h2>\n\n <ul>\n <li>\n Retatrutide is a triple-receptor agonist targeting GLP-1, GIP and\n glucagon receptors.\n <\/li>\n <li>\n It is not simply a GLP-1 agonist and should not be described as an\n approved weight-loss medicine.\n <\/li>\n <li>\n A Phase 2 obesity trial included 338 adults with obesity or\n overweight and a weight-related condition.\n <\/li>\n <li>\n The 12 mg group experienced a mean body-weight reduction of 24.2%\n at 48 weeks.\n <\/li>\n <li>\n Gastrointestinal adverse events were common, particularly during\n dose escalation.\n <\/li>\n <li>\n Additional research is required to assess long-term safety and\n clinical outcomes.\n <\/li>\n <\/ul>\n <\/aside>\n\n <section aria-labelledby=\"what-is-retatrutide\">\n <h2 id=\"what-is-retatrutide\">What Is Retatrutide?<\/h2>\n\n <p>\n Retatrutide is a peptide-based investigational compound developed to\n activate three metabolic hormone receptors within a single molecule.\n It is being evaluated for its potential effects on appetite\n regulation, glucose metabolism, lipid metabolism and energy\n expenditure.\n <\/p>\n\n <p>\n Retatrutide differs from single-receptor compounds such as\n semaglutide and dual-receptor compounds such as tirzepatide. Its\n scientific significance comes from the interaction among all three\n receptor pathways rather than from a simple or direct\n \u201cfat-burning\u201d effect.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"how-it-works\">\n <h2 id=\"how-it-works\">How Does Retatrutide Work?<\/h2>\n\n <h3>GLP-1 receptor activation<\/h3>\n\n <p>\n GLP-1 is an incretin hormone involved in post-meal glucose regulation\n and appetite signalling. GLP-1 receptor activity is associated with:\n <\/p>\n\n <ul>\n <li>Glucose-dependent insulin secretion<\/li>\n <li>Reduced glucagon secretion under certain conditions<\/li>\n <li>Delayed gastric emptying<\/li>\n <li>Central signalling associated with appetite and satiety<\/li>\n <\/ul>\n\n <h3>GIP receptor activation<\/h3>\n\n <p>\n GIP is another incretin hormone involved in nutrient handling and\n insulin signalling. Researchers are investigating whether combined\n GLP-1 and GIP activity can produce broader metabolic effects than\n GLP-1 activity alone.\n <\/p>\n\n <ul>\n <li>Supports glucose-dependent insulin responses<\/li>\n <li>Influences nutrient and lipid metabolism<\/li>\n <li>May complement GLP-1 receptor signalling<\/li>\n <li>May affect adipose-tissue biology<\/li>\n <\/ul>\n\n <h3>Glucagon receptor activation<\/h3>\n\n <p>\n Glucagon receptor activity is the feature that most clearly\n distinguishes retatrutide from established single- and dual-agonist\n compounds. This pathway may affect hepatic metabolism and energy\n expenditure.\n <\/p>\n\n <p>\n Glucagon activity can also increase hepatic glucose production.\n Consequently, researchers must evaluate the balance between potential\n effects on energy expenditure and possible glucose-related risks. The\n interaction of all three pathways is more complex than a standalone\n fat-oxidation mechanism.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"clinical-evidence\">\n <h2 id=\"clinical-evidence\">What Did the Phase 2 Obesity Trial Find?<\/h2>\n\n <p>\n A randomised Phase 2 trial published in the\n <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener noreferrer\">\n New England Journal of Medicine\n <\/a>\n assessed retatrutide in 338 adults with obesity or overweight and at\n least one weight-related condition. Participants in this trial did\n not have diabetes.\n <\/p>\n\n <div class=\"responsive-table\">\n <table>\n <caption>\n Selected mean body-weight changes reported at 48 weeks\n <\/caption>\n <thead>\n <tr>\n <th scope=\"col\">Study group<\/th>\n <th scope=\"col\">Mean body-weight change<\/th>\n <th scope=\"col\">Research context<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <th scope=\"row\">Retatrutide 4 mg<\/th>\n <td>Approximately \u221217.1%<\/td>\n <td>Investigational once-weekly study regimen<\/td>\n <\/tr>\n <tr>\n <th scope=\"row\">Retatrutide 8 mg<\/th>\n <td>Approximately \u221222.8%<\/td>\n <td>Investigational once-weekly study regimen<\/td>\n <\/tr>\n <tr>\n <th scope=\"row\">Retatrutide 12 mg<\/th>\n <td>Approximately \u221224.2%<\/td>\n <td>Highest maintenance dose evaluated in the trial<\/td>\n <\/tr>\n <tr>\n <th scope=\"row\">Placebo<\/th>\n <td>Approximately \u22122.1%<\/td>\n <td>Comparator group<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n <p>\n These results are group averages from a controlled clinical trial.\n They do not guarantee an individual outcome and must not be used to\n create personal treatment expectations or dosing plans.\n <\/p>\n\n <p>\n It is also important not to confuse the reported <strong>24.2% mean\n weight reduction<\/strong> with a 24 mg dose. The highest maintenance\n dose evaluated in the published Phase 2 obesity trial was\n <strong>12 mg once weekly<\/strong>.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"metabolic-findings\">\n <h2 id=\"metabolic-findings\">Findings Beyond Body Weight<\/h2>\n\n <p>\n Clinical research has also examined measurements beyond total body\n weight. Reported findings have included changes in:\n <\/p>\n\n <ul>\n <li>Waist circumference<\/li>\n <li>Blood pressure<\/li>\n <li>Fasting glucose and insulin-related measurements<\/li>\n <li>Triglycerides and other lipid measurements<\/li>\n <li>Liver fat in selected research populations<\/li>\n <\/ul>\n\n <p>\n These findings are scientifically important, but they do not by\n themselves prove that retatrutide prevents or treats cardiovascular\n disease, diabetes, fatty liver disease or another medical condition.\n Disease-specific benefits must be established through appropriately\n designed trials.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"safety\">\n <h2 id=\"safety\">Safety Findings and Research Limitations<\/h2>\n\n <p>\n The most frequently reported adverse events in the Phase 2 obesity\n trial were gastrointestinal. They were generally mild to moderate and\n occurred more often during dose escalation.\n <\/p>\n\n <ul>\n <li>Nausea<\/li>\n <li>Diarrhoea<\/li>\n <li>Vomiting<\/li>\n <li>Constipation<\/li>\n <li>Reduced appetite<\/li>\n <\/ul>\n\n <p>\n Dose-dependent increases in heart rate were also observed. Larger and\n longer studies are needed to assess uncommon adverse events,\n discontinuation rates, long-term cardiovascular outcomes and what\n happens after treatment is stopped.\n <\/p>\n\n <div class=\"safety-notice\" role=\"note\">\n <h2>Important Safety Notice<\/h2>\n\n <p>\n This article is for general scientific education only. It does not\n provide medical advice, personal dosing instructions or a\n recommendation to use retatrutide.\n <\/p>\n\n <p>\n A product described as \u201cresearch use only\u201d must not be administered\n to humans or used as a substitute for an authorised medicine.\n <\/p>\n <\/div>\n <\/section>\n\n <section aria-labelledby=\"availability\">\n <h2 id=\"availability\">Is Retatrutide Available as an Approved Medicine?<\/h2>\n\n <p>\n Retatrutide has been studied as an investigational compound.\n Regulatory status can change, so readers in the United Kingdom should\n consult the official\n <a href=\"https:\/\/www.gov.uk\/government\/organisations\/medicines-and-healthcare-products-regulatory-agency\" target=\"_blank\" rel=\"noopener noreferrer\">\n Medicines and Healthcare products Regulatory Agency\n <\/a>\n for current authorisation information.\n <\/p>\n\n <p>\n Terms such as \u201cresearch-grade,\u201d \u201ccompounded\u201d and \u201cindependently\n tested\u201d do not mean that a product has been authorised as a medicine\n or shown to be safe for personal administration.\n <\/p>\n <\/section>\n\n <aside class=\"research-notice\" aria-labelledby=\"research-use-heading\">\n <h2 id=\"research-use-heading\">ALLUVI Research-Use Notice<\/h2>\n\n <p>\n Any ALLUVI retatrutide material listed through\n <a href=\"https:\/\/alluvipeptideshop.co.uk\/en_au\/\">\n alluvipeptideshop.co.uk\n <\/a>\n is presented exclusively as a laboratory research material.\n <\/p>\n\n <ul>\n <li>Not for human consumption or administration<\/li>\n <li>Not for veterinary use<\/li>\n <li>Not for diagnosis, treatment or disease prevention<\/li>\n <li>Not for personal weight management<\/li>\n <li>Not a substitute for an authorised prescription medicine<\/li>\n <\/ul>\n\n <p>\n A Certificate of Analysis reports findings for the identified sample\n or batch. It does not establish clinical safety, medicinal approval or\n suitability for human use.\n <\/p>\n <\/aside>\n\n <section aria-labelledby=\"faq\">\n <h2 id=\"faq\">Frequently Asked Questions<\/h2>\n\n <div class=\"faq-item\">\n <h3>Is retatrutide only a GLP-1 agonist?<\/h3>\n <p>\n No. Retatrutide is designed to activate GLP-1, GIP and glucagon\n receptors, making it a triple-receptor agonist.\n <\/p>\n <\/div>\n\n <div class=\"faq-item\">\n <h3>Does retatrutide directly burn body fat?<\/h3>\n <p>\n \u201cFat burning\u201d is an oversimplification. Researchers are studying\n how the compound affects appetite, nutrient metabolism, glucose\n regulation and energy expenditure through several interacting\n receptor pathways.\n <\/p>\n <\/div>\n\n <div class=\"faq-item\">\n <h3>Did participants receive 24 mg in the Phase 2 obesity trial?<\/h3>\n <p>\n No. The highest maintenance dose in the published trial was 12 mg.\n The 24.2 figure refers to the percentage of mean body-weight\n reduction reported at 48 weeks in that group.\n <\/p>\n <\/div>\n\n <div class=\"faq-item\">\n <h3>Can research-only retatrutide be used for weight management?<\/h3>\n <p>\n No. Research-only materials are not authorised medicines and must\n not be administered to humans or used for self-treatment.\n <\/p>\n <\/div>\n <\/section>\n\n <section aria-labelledby=\"sources\">\n <h2 id=\"sources\">Scientific Sources and Further Reading<\/h2>\n\n <ol class=\"sources\">\n <li>\n Jastreboff AM, et al.\n <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener noreferrer\">\n Triple-Hormone-Receptor Agonist Retatrutide for Obesity:\n A Phase 2 Trial\n <\/a>.\n <em>New England Journal of Medicine<\/em>, 2023.\n <\/li>\n\n <li>\n PubMed:\n <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n Retatrutide Phase 2 obesity trial record\n <\/a>.\n <\/li>\n\n <li>\n NIHR Be Part of Research:\n <a href=\"https:\/\/bepartofresearch.nihr.ac.uk\/trial-details\/trial-detail?trialId=39626\" target=\"_blank\" rel=\"noopener noreferrer\">\n Retatrutide clinical research information\n <\/a>.\n <\/li>\n <\/ol>\n <\/section>\n\n <div class=\"research-button-container\">\n <a class=\"research-button\" href=\"https:\/\/alluvipeptideshop.co.uk\/en_au\/\" aria-label=\"Visit ALLUVI Peptide Shop for laboratory research information\">\n View Laboratory Research Information\n <\/a>\n <\/div>\n\n <footer class=\"article-footer\">\n <p>\n <strong>Last reviewed:<\/strong>\n <time datetime=\"2026-07\">July 2026<\/time>\n <\/p>\n\n <p>\n <strong>Medical disclaimer:<\/strong>\n This page is provided for general scientific education only. It does\n not diagnose, treat, cure or prevent any condition and must not be\n used to make personal treatment or dosing decisions. Speak with a\n qualified healthcare professional about authorised approaches to\n weight management.\n <\/p>\n <\/footer>\n <\/article>\n <\/main>\n<\/body>\n<\/html>","protected":false},"excerpt":{"rendered":"<p>Understanding Retatrutide: Mechanism, Trial Results and Safety Understanding Retatrutide: Mechanism, Trial Results and Safety Retatrutide is an investigational peptide being studied for obesity and related metabolic conditions. Rather than acting only at the GLP-1 receptor, retatrutide is designed to activate three receptor systems: GLP-1, GIP and glucagon. This triple-agonist mechanism has produced notable findings in […]","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[37],"tags":[],"class_list":["post-1666","post","type-post","status-publish","format-standard","hentry","category-alluvi-uk-reviews"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts\/1666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/comments?post=1666"}],"version-history":[{"count":1,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts\/1666\/revisions"}],"predecessor-version":[{"id":1676,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts\/1666\/revisions\/1676"}],"wp:attachment":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/media?parent=1666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/categories?post=1666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/tags?post=1666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

{"id":1666,"date":"2026-02-10T20:16:50","date_gmt":"2026-02-10T19:16:50","guid":{"rendered":"https:\/\/retavital.com\/?p=1666"},"modified":"2026-07-24T00:30:52","modified_gmt":"2026-07-24T00:30:52","slug":"how-retatrutide-helps-in-fat-burning-an","status":"publish","type":"post","link":"https:\/\/alluvipeptideshop.co.uk\/en_au\/how-retatrutide-helps-in-fat-burning-an\/","title":{"rendered":"Understanding Retatrutide: A Revolutionary Weight Loss Solution"},"content":{"rendered":"\n\n\n \n \n\n Understanding Retatrutide: Mechanism, Trial Results and Safety<\/title>\n\n <meta\n name=\"description\"\n content=\"Learn how retatrutide targets GLP-1, GIP and glucagon receptors, what its Phase 2 obesity trial found, and why it remains an investigational compound.\"\n >\n\n <meta name=\"robots\" content=\"index, follow, max-image-preview:large\">\n <meta name=\"author\" content=\"ALLUVI Peptide Shop\">\n\n <meta\n property=\"og:title\"\n content=\"Understanding Retatrutide: Mechanism, Trial Results and Safety\"\n >\n <meta\n property=\"og:description\"\n content=\"An evidence-based overview of retatrutide's triple-agonist mechanism, published obesity research, safety findings and investigational status.\"\n >\n <meta property=\"og:type\" content=\"article\">\n <meta\n property=\"og:image\"\n content=\"https:\/\/alluvipeptideshop.co.uk\/wp-content\/uploads\/2026\/02\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n >\n <meta property=\"og:site_name\" content=\"ALLUVI Peptide Shop\">\n\n <meta name=\"twitter:card\" content=\"summary_large_image\">\n <meta\n name=\"twitter:title\"\n content=\"Understanding Retatrutide: Mechanism, Trial Results and Safety\"\n >\n <meta\n name=\"twitter:description\"\n content=\"Explore retatrutide's triple-agonist mechanism, Phase 2 findings and important safety limitations.\"\n >\n <meta\n name=\"twitter:image\"\n content=\"https:\/\/alluvipeptideshop.co.uk\/wp-content\/uploads\/2026\/02\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n >\n\n <style>\n :root {\n --orange: #ff8000;\n --orange-dark: #cc6600;\n --black: #111111;\n --text: #333333;\n --muted: #666666;\n --light: #f8f9fa;\n --border: #dddddd;\n --warning-bg: #fff3cd;\n --warning-border: #ffc107;\n --danger-border: #dc3545;\n }\n\n * {\n box-sizing: border-box;\n }\n\n html {\n scroll-behavior: smooth;\n }\n\n body {\n margin: 0;\n background: #ffffff;\n color: var(--text);\n font-family: Arial, Helvetica, sans-serif;\n font-size: 17px;\n line-height: 1.7;\n }\n\n .article-container {\n width: min(100% - 32px, 920px);\n margin: 0 auto;\n padding: 40px 0;\n }\n\n h1,\n h2,\n h3 {\n color: var(--black);\n line-height: 1.3;\n }\n\n h1 {\n margin: 0 0 20px;\n font-size: clamp(2rem, 5vw, 3rem);\n }\n\n h2 {\n margin-top: 42px;\n padding-bottom: 8px;\n border-bottom: 3px solid var(--orange);\n font-size: clamp(1.5rem, 4vw, 2rem);\n }\n\n h3 {\n margin-top: 28px;\n font-size: 1.3rem;\n }\n\n p,\n li {\n max-width: 78ch;\n }\n\n a {\n color: var(--orange-dark);\n font-weight: 600;\n }\n\n a:hover,\n a:focus {\n color: var(--orange);\n }\n\n .intro {\n color: #444444;\n font-size: 1.1rem;\n }\n\n .article-image {\n display: block;\n width: 100%;\n max-width: 800px;\n height: auto;\n margin: 28px auto 10px;\n border: 1px solid var(--border);\n border-radius: 8px;\n }\n\n .image-caption {\n margin: 0 auto 28px;\n color: var(--muted);\n font-size: 0.9rem;\n text-align: center;\n }\n\n .key-points,\n .research-notice,\n .safety-notice {\n margin: 28px 0;\n padding: 20px;\n border-radius: 6px;\n }\n\n .key-points {\n background: var(--light);\n border-left: 5px solid var(--orange);\n }\n\n .research-notice {\n background: var(--warning-bg);\n border-left: 5px solid var(--warning-border);\n }\n\n .safety-notice {\n background: var(--light);\n border-left: 5px solid var(--danger-border);\n }\n\n .key-points h2,\n .research-notice h2,\n .safety-notice h2 {\n margin-top: 0;\n padding: 0;\n border: 0;\n font-size: 1.35rem;\n }\n\n .responsive-table {\n width: 100%;\n margin: 24px 0;\n overflow-x: auto;\n }\n\n table {\n width: 100%;\n min-width: 680px;\n border-collapse: collapse;\n }\n\n caption {\n padding: 10px 0;\n font-weight: 700;\n text-align: left;\n }\n\n th,\n td {\n padding: 12px;\n border: 1px solid var(--border);\n text-align: left;\n vertical-align: top;\n }\n\n thead {\n background: var(--black);\n color: #ffffff;\n }\n\n .faq-item {\n margin: 18px 0;\n padding: 18px 20px;\n background: var(--light);\n border: 1px solid var(--border);\n border-radius: 6px;\n }\n\n .faq-item h3 {\n margin: 0 0 8px;\n }\n\n .faq-item p {\n margin: 0;\n }\n\n .sources li {\n margin-bottom: 14px;\n }\n\n .research-button-container {\n margin: 30px 0;\n text-align: center;\n }\n\n .research-button {\n display: inline-block;\n padding: 13px 24px;\n background: var(--orange);\n color: #ffffff;\n border-radius: 5px;\n font-weight: 700;\n text-decoration: none;\n }\n\n .research-button:hover,\n .research-button:focus {\n background: var(--orange-dark);\n color: #ffffff;\n }\n\n .article-footer {\n margin-top: 42px;\n padding-top: 22px;\n border-top: 2px solid var(--border);\n color: #555555;\n font-size: 0.92rem;\n }\n\n @media (max-width: 600px) {\n body {\n font-size: 16px;\n }\n\n .article-container {\n width: min(100% - 24px, 920px);\n padding: 24px 0;\n }\n }\n <\/style>\n\n <script type=\"application\/ld+json\">{\n \"@context\": \"https:\\\/\\\/schema.org\",\n \"@type\": \"Article\",\n \"headline\": \"Understanding Retatrutide: Mechanism, Trial Results and Safety\",\n \"description\": \"An evidence-based overview of retatrutide's triple-agonist mechanism, published obesity research, safety findings and investigational status.\",\n \"image\": [\n \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n ],\n \"author\": {\n \"@type\": \"Organization\",\n \"name\": \"ALLUVI Peptide Shop\",\n \"url\": \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/\"\n },\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"ALLUVI Peptide Shop\",\n \"url\": \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/\"\n },\n \"mainEntityOfPage\": {\n \"@type\": \"WebPage\",\n \"@id\": \"https:\\\/\\\/alluvipeptideshop.co.uk\\\/\"\n },\n \"about\": [\n {\n \"@type\": \"Thing\",\n \"name\": \"Retatrutide\"\n },\n {\n \"@type\": \"Thing\",\n \"name\": \"Obesity research\"\n },\n {\n \"@type\": \"Thing\",\n \"name\": \"Triple receptor agonist\"\n }\n ]\n}<\/script>\n<\/head>\n\n<body>\n <main>\n <article class=\"article-container\">\n <header>\n <h1>Understanding Retatrutide: Mechanism, Trial Results and Safety<\/h1>\n\n <p class=\"intro\">\n Retatrutide is an investigational peptide being studied for obesity\n and related metabolic conditions. Rather than acting only at the\n GLP-1 receptor, retatrutide is designed to activate three receptor\n systems: GLP-1, GIP and glucagon.\n <\/p>\n\n <p>\n This triple-agonist mechanism has produced notable findings in\n clinical research. However, retatrutide should not be described as an\n approved weight-loss treatment, a guaranteed fat-burning product or a\n substitute for an authorised medicine.\n <\/p>\n <\/header>\n\n <figure>\n <img decoding=\"async\"\n class=\"article-image\"\n src=\"https:\/\/alluvipeptideshop.co.uk\/wp-content\/uploads\/2026\/02\/Retatrutide-reduces-body-wieght-chart-outcome.jpg\"\n alt=\"Chart illustrating body-weight changes reported during retatrutide research\"\n width=\"800\"\n height=\"800\"\n loading=\"eager\"\n fetchpriority=\"high\"\n >\n <figcaption class=\"image-caption\">\n Illustration of body-weight outcomes associated with published\n retatrutide research. Study averages do not predict individual results.\n <\/figcaption>\n <\/figure>\n\n <aside class=\"key-points\" aria-labelledby=\"key-points-heading\">\n <h2 id=\"key-points-heading\">Key Points<\/h2>\n\n <ul>\n <li>\n Retatrutide is a triple-receptor agonist targeting GLP-1, GIP and\n glucagon receptors.\n <\/li>\n <li>\n It is not simply a GLP-1 agonist and should not be described as an\n approved weight-loss medicine.\n <\/li>\n <li>\n A Phase 2 obesity trial included 338 adults with obesity or\n overweight and a weight-related condition.\n <\/li>\n <li>\n The 12 mg group experienced a mean body-weight reduction of 24.2%\n at 48 weeks.\n <\/li>\n <li>\n Gastrointestinal adverse events were common, particularly during\n dose escalation.\n <\/li>\n <li>\n Additional research is required to assess long-term safety and\n clinical outcomes.\n <\/li>\n <\/ul>\n <\/aside>\n\n <section aria-labelledby=\"what-is-retatrutide\">\n <h2 id=\"what-is-retatrutide\">What Is Retatrutide?<\/h2>\n\n <p>\n Retatrutide is a peptide-based investigational compound developed to\n activate three metabolic hormone receptors within a single molecule.\n It is being evaluated for its potential effects on appetite\n regulation, glucose metabolism, lipid metabolism and energy\n expenditure.\n <\/p>\n\n <p>\n Retatrutide differs from single-receptor compounds such as\n semaglutide and dual-receptor compounds such as tirzepatide. Its\n scientific significance comes from the interaction among all three\n receptor pathways rather than from a simple or direct\n \u201cfat-burning\u201d effect.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"how-it-works\">\n <h2 id=\"how-it-works\">How Does Retatrutide Work?<\/h2>\n\n <h3>GLP-1 receptor activation<\/h3>\n\n <p>\n GLP-1 is an incretin hormone involved in post-meal glucose regulation\n and appetite signalling. GLP-1 receptor activity is associated with:\n <\/p>\n\n <ul>\n <li>Glucose-dependent insulin secretion<\/li>\n <li>Reduced glucagon secretion under certain conditions<\/li>\n <li>Delayed gastric emptying<\/li>\n <li>Central signalling associated with appetite and satiety<\/li>\n <\/ul>\n\n <h3>GIP receptor activation<\/h3>\n\n <p>\n GIP is another incretin hormone involved in nutrient handling and\n insulin signalling. Researchers are investigating whether combined\n GLP-1 and GIP activity can produce broader metabolic effects than\n GLP-1 activity alone.\n <\/p>\n\n <ul>\n <li>Supports glucose-dependent insulin responses<\/li>\n <li>Influences nutrient and lipid metabolism<\/li>\n <li>May complement GLP-1 receptor signalling<\/li>\n <li>May affect adipose-tissue biology<\/li>\n <\/ul>\n\n <h3>Glucagon receptor activation<\/h3>\n\n <p>\n Glucagon receptor activity is the feature that most clearly\n distinguishes retatrutide from established single- and dual-agonist\n compounds. This pathway may affect hepatic metabolism and energy\n expenditure.\n <\/p>\n\n <p>\n Glucagon activity can also increase hepatic glucose production.\n Consequently, researchers must evaluate the balance between potential\n effects on energy expenditure and possible glucose-related risks. The\n interaction of all three pathways is more complex than a standalone\n fat-oxidation mechanism.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"clinical-evidence\">\n <h2 id=\"clinical-evidence\">What Did the Phase 2 Obesity Trial Find?<\/h2>\n\n <p>\n A randomised Phase 2 trial published in the\n <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener noreferrer\">\n New England Journal of Medicine\n <\/a>\n assessed retatrutide in 338 adults with obesity or overweight and at\n least one weight-related condition. Participants in this trial did\n not have diabetes.\n <\/p>\n\n <div class=\"responsive-table\">\n <table>\n <caption>\n Selected mean body-weight changes reported at 48 weeks\n <\/caption>\n <thead>\n <tr>\n <th scope=\"col\">Study group<\/th>\n <th scope=\"col\">Mean body-weight change<\/th>\n <th scope=\"col\">Research context<\/th>\n <\/tr>\n <\/thead>\n <tbody>\n <tr>\n <th scope=\"row\">Retatrutide 4 mg<\/th>\n <td>Approximately \u221217.1%<\/td>\n <td>Investigational once-weekly study regimen<\/td>\n <\/tr>\n <tr>\n <th scope=\"row\">Retatrutide 8 mg<\/th>\n <td>Approximately \u221222.8%<\/td>\n <td>Investigational once-weekly study regimen<\/td>\n <\/tr>\n <tr>\n <th scope=\"row\">Retatrutide 12 mg<\/th>\n <td>Approximately \u221224.2%<\/td>\n <td>Highest maintenance dose evaluated in the trial<\/td>\n <\/tr>\n <tr>\n <th scope=\"row\">Placebo<\/th>\n <td>Approximately \u22122.1%<\/td>\n <td>Comparator group<\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n\n <p>\n These results are group averages from a controlled clinical trial.\n They do not guarantee an individual outcome and must not be used to\n create personal treatment expectations or dosing plans.\n <\/p>\n\n <p>\n It is also important not to confuse the reported <strong>24.2% mean\n weight reduction<\/strong> with a 24 mg dose. The highest maintenance\n dose evaluated in the published Phase 2 obesity trial was\n <strong>12 mg once weekly<\/strong>.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"metabolic-findings\">\n <h2 id=\"metabolic-findings\">Findings Beyond Body Weight<\/h2>\n\n <p>\n Clinical research has also examined measurements beyond total body\n weight. Reported findings have included changes in:\n <\/p>\n\n <ul>\n <li>Waist circumference<\/li>\n <li>Blood pressure<\/li>\n <li>Fasting glucose and insulin-related measurements<\/li>\n <li>Triglycerides and other lipid measurements<\/li>\n <li>Liver fat in selected research populations<\/li>\n <\/ul>\n\n <p>\n These findings are scientifically important, but they do not by\n themselves prove that retatrutide prevents or treats cardiovascular\n disease, diabetes, fatty liver disease or another medical condition.\n Disease-specific benefits must be established through appropriately\n designed trials.\n <\/p>\n <\/section>\n\n <section aria-labelledby=\"safety\">\n <h2 id=\"safety\">Safety Findings and Research Limitations<\/h2>\n\n <p>\n The most frequently reported adverse events in the Phase 2 obesity\n trial were gastrointestinal. They were generally mild to moderate and\n occurred more often during dose escalation.\n <\/p>\n\n <ul>\n <li>Nausea<\/li>\n <li>Diarrhoea<\/li>\n <li>Vomiting<\/li>\n <li>Constipation<\/li>\n <li>Reduced appetite<\/li>\n <\/ul>\n\n <p>\n Dose-dependent increases in heart rate were also observed. Larger and\n longer studies are needed to assess uncommon adverse events,\n discontinuation rates, long-term cardiovascular outcomes and what\n happens after treatment is stopped.\n <\/p>\n\n <div class=\"safety-notice\" role=\"note\">\n <h2>Important Safety Notice<\/h2>\n\n <p>\n This article is for general scientific education only. It does not\n provide medical advice, personal dosing instructions or a\n recommendation to use retatrutide.\n <\/p>\n\n <p>\n A product described as \u201cresearch use only\u201d must not be administered\n to humans or used as a substitute for an authorised medicine.\n <\/p>\n <\/div>\n <\/section>\n\n <section aria-labelledby=\"availability\">\n <h2 id=\"availability\">Is Retatrutide Available as an Approved Medicine?<\/h2>\n\n <p>\n Retatrutide has been studied as an investigational compound.\n Regulatory status can change, so readers in the United Kingdom should\n consult the official\n <a href=\"https:\/\/www.gov.uk\/government\/organisations\/medicines-and-healthcare-products-regulatory-agency\" target=\"_blank\" rel=\"noopener noreferrer\">\n Medicines and Healthcare products Regulatory Agency\n <\/a>\n for current authorisation information.\n <\/p>\n\n <p>\n Terms such as \u201cresearch-grade,\u201d \u201ccompounded\u201d and \u201cindependently\n tested\u201d do not mean that a product has been authorised as a medicine\n or shown to be safe for personal administration.\n <\/p>\n <\/section>\n\n <aside class=\"research-notice\" aria-labelledby=\"research-use-heading\">\n <h2 id=\"research-use-heading\">ALLUVI Research-Use Notice<\/h2>\n\n <p>\n Any ALLUVI retatrutide material listed through\n <a href=\"https:\/\/alluvipeptideshop.co.uk\/en_au\/\">\n alluvipeptideshop.co.uk\n <\/a>\n is presented exclusively as a laboratory research material.\n <\/p>\n\n <ul>\n <li>Not for human consumption or administration<\/li>\n <li>Not for veterinary use<\/li>\n <li>Not for diagnosis, treatment or disease prevention<\/li>\n <li>Not for personal weight management<\/li>\n <li>Not a substitute for an authorised prescription medicine<\/li>\n <\/ul>\n\n <p>\n A Certificate of Analysis reports findings for the identified sample\n or batch. It does not establish clinical safety, medicinal approval or\n suitability for human use.\n <\/p>\n <\/aside>\n\n <section aria-labelledby=\"faq\">\n <h2 id=\"faq\">Frequently Asked Questions<\/h2>\n\n <div class=\"faq-item\">\n <h3>Is retatrutide only a GLP-1 agonist?<\/h3>\n <p>\n No. Retatrutide is designed to activate GLP-1, GIP and glucagon\n receptors, making it a triple-receptor agonist.\n <\/p>\n <\/div>\n\n <div class=\"faq-item\">\n <h3>Does retatrutide directly burn body fat?<\/h3>\n <p>\n \u201cFat burning\u201d is an oversimplification. Researchers are studying\n how the compound affects appetite, nutrient metabolism, glucose\n regulation and energy expenditure through several interacting\n receptor pathways.\n <\/p>\n <\/div>\n\n <div class=\"faq-item\">\n <h3>Did participants receive 24 mg in the Phase 2 obesity trial?<\/h3>\n <p>\n No. The highest maintenance dose in the published trial was 12 mg.\n The 24.2 figure refers to the percentage of mean body-weight\n reduction reported at 48 weeks in that group.\n <\/p>\n <\/div>\n\n <div class=\"faq-item\">\n <h3>Can research-only retatrutide be used for weight management?<\/h3>\n <p>\n No. Research-only materials are not authorised medicines and must\n not be administered to humans or used for self-treatment.\n <\/p>\n <\/div>\n <\/section>\n\n <section aria-labelledby=\"sources\">\n <h2 id=\"sources\">Scientific Sources and Further Reading<\/h2>\n\n <ol class=\"sources\">\n <li>\n Jastreboff AM, et al.\n <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2301972\" target=\"_blank\" rel=\"noopener noreferrer\">\n Triple-Hormone-Receptor Agonist Retatrutide for Obesity:\n A Phase 2 Trial\n <\/a>.\n <em>New England Journal of Medicine<\/em>, 2023.\n <\/li>\n\n <li>\n PubMed:\n <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37385280\/\" target=\"_blank\" rel=\"noopener noreferrer\">\n Retatrutide Phase 2 obesity trial record\n <\/a>.\n <\/li>\n\n <li>\n NIHR Be Part of Research:\n <a href=\"https:\/\/bepartofresearch.nihr.ac.uk\/trial-details\/trial-detail?trialId=39626\" target=\"_blank\" rel=\"noopener noreferrer\">\n Retatrutide clinical research information\n <\/a>.\n <\/li>\n <\/ol>\n <\/section>\n\n <div class=\"research-button-container\">\n <a class=\"research-button\" href=\"https:\/\/alluvipeptideshop.co.uk\/en_au\/\" aria-label=\"Visit ALLUVI Peptide Shop for laboratory research information\">\n View Laboratory Research Information\n <\/a>\n <\/div>\n\n <footer class=\"article-footer\">\n <p>\n <strong>Last reviewed:<\/strong>\n <time datetime=\"2026-07\">July 2026<\/time>\n <\/p>\n\n <p>\n <strong>Medical disclaimer:<\/strong>\n This page is provided for general scientific education only. It does\n not diagnose, treat, cure or prevent any condition and must not be\n used to make personal treatment or dosing decisions. Speak with a\n qualified healthcare professional about authorised approaches to\n weight management.\n <\/p>\n <\/footer>\n <\/article>\n <\/main>\n<\/body>\n<\/html>","protected":false},"excerpt":{"rendered":"<p>Understanding Retatrutide: Mechanism, Trial Results and Safety Understanding Retatrutide: Mechanism, Trial Results and Safety Retatrutide is an investigational peptide being studied for obesity and related metabolic conditions. Rather than acting only at the GLP-1 receptor, retatrutide is designed to activate three receptor systems: GLP-1, GIP and glucagon. This triple-agonist mechanism has produced notable findings in […]","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[37],"tags":[],"class_list":["post-1666","post","type-post","status-publish","format-standard","hentry","category-alluvi-uk-reviews"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts\/1666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/comments?post=1666"}],"version-history":[{"count":1,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts\/1666\/revisions"}],"predecessor-version":[{"id":1676,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/posts\/1666\/revisions\/1676"}],"wp:attachment":[{"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/media?parent=1666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/categories?post=1666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alluvipeptideshop.co.uk\/en_au\/wp-json\/wp\/v2\/tags?post=1666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}